HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 335 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,211,513 | +24.1% | 31,715 | +17.2% | 0.02% | +13.3% |
| Q2 2023 | $975,874 | -37.3% | 27,055 | -33.6% | 0.02% | -42.3% |
| Q1 2023 | $1,556,624 | -75.7% | 40,760 | -63.7% | 0.03% | -79.4% |
| Q4 2022 | $6,393,569 | +42.6% | 112,365 | -0.9% | 0.13% | +34.0% |
| Q3 2022 | $4,485,000 | +17.3% | 113,425 | +30.5% | 0.09% | -18.3% |
| Q2 2022 | $3,825,000 | +48.6% | 86,925 | +34.7% | 0.12% | +88.5% |
| Q1 2022 | $2,574,000 | -22.4% | 64,532 | -21.7% | 0.06% | 0.0% |
| Q4 2021 | $3,315,000 | -15.5% | 82,446 | -14.5% | 0.06% | -6.2% |
| Q3 2021 | $3,921,000 | -19.6% | 96,395 | -10.3% | 0.06% | -17.7% |
| Q2 2021 | $4,879,000 | +13.8% | 107,435 | +4.5% | 0.08% | +1.3% |
| Q1 2021 | $4,287,000 | -23.2% | 102,830 | -21.4% | 0.08% | -11.4% |
| Q4 2020 | $5,584,000 | – | 130,750 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |